Pharmacyclics, Inc (NASDAQ:PCYC)’s Price Target Increased

0
843

Dallas, Texas 03/28/2014 (FINANCIALSTRENDS) – Morgan Stanley has assumed coverage on Pharmacyclics, Inc (NASDAQ:PCYC) shares of Pharmacyclics (NASDAQ:PCYC) in a report released on Wednesday, Stock. The firm has assigned an “equal weight” rating and a price target of $120.00 on the stock. Recently, numerous other analysts have commented on the company stock. Analysts at the Roth Capital firm have upped their price target on Pharmacyclics, Inc (NASDAQ:PCYC) shares to $183.00 in the research note on 24 February. Separately, Zacks analysts have reiterated their neutral rating on Pharmacyclics, Inc (NASDAQ:PCYC) shares in the research note on 24 February.

They have now set a price target of $159.00 on the stock. Finally, the analysts at Deutsche Bank have raised their PT on Pharmacyclics, Inc (NASDAQ:PCYC) shares from $170.00 up to $180.00 in the research note on 21 February. They have now set a rating of “buy rating on the company stock. Four research analysts have rated the Pharmacyclics, Inc (NASDAQ:PCYC) stock with a “hold” rating and 8 have given a “buy” rating to the company. Currently, the average rating on Pharmacyclics, Inc (NASDAQ:PCYC) is a “buy” and the average PT is $156.25.

Pharmacyclics (NASDAQ:PCYC) last issued the company’s quarterly-earnings data on 20 February. It reported earnings per share of $0.95 for the quarter, which topped the average analysts’ projections of beating of $0.67 by $0.28. Pharmacyclics, Inc (NASDAQ:PCYC) had revenue of $123.60M for the quarter, in comparison to the average projection of $85.69 million. On an average, analysts project that Pharmacyclics, Inc (NASDAQ:PCYC) will post earnings per share of $0.11 for the current financial year.

Pharmacyclics, Inc (NASDAQ:PCYC) is a clinical stage bio pharmaceutical company that is focused on the development & commercializing of the small-molecule drugs used to treat cancer & immune mediated diseases. Its clinical development & product candidates are the small-molecule enzyme-inhibitors that are designed to target the biochemical pathways that are involved in human diseases.

This report is for information purposes only, and is neither a solicitation or recommendation to buy nor an offer to sell securities. Financials Trend is not-a-registered-investment-advisor. Financials Trend is not a broker-dealer. Information, opinions and analysis contained herein are based on sources believed to be reliable, but no representation, expressed or implied, is made as to its accuracy, completeness or correctness. The opinions contained herein reflect our current judgment and are subject to change without notice. Financials Trend accepts no liability for any losses arising from an investor's reliance on the use of this material. Financials Trend sometimes gets compensated up to one hundred and fifty thousand dollars per month for featuring particular stocks. See site disclaimer for complete compensation. Financials Trend and its affiliates or officers currently hold no shares of these stocks. Financials Trend and its affiliates or officers will purchase and sell shares of common stock of these stocks, in the open market at any time without notice. Financials Trend will not update its purchases and sales of these stocks in any future postings on Financials Trend's websites. Certain information included herein is forward-looking within the context of the Private Securities Litigation Reform Act of 1995, including, but not limited to, statements concerning manufacturing, marketing, growth, and expansion. The words "may", "would," "will," "expect," "estimate," "anticipate," "believe," "intend," " project," and similar expressions and variations thereof are intended to identify for ward-looking statements. Such forward- looking information involves important risks and uncertainties that could affect actual results and cause them to differ materially from expectations expressed herein. *Financials Trend does not set price targets on securities. Never invest into a stock discussed on this web site or in this email alert unless you can afford to lose your entire investment.